Social Links

Follow on Facebook Follow on Twitter Follow on G+Follow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

DNRS Roof Banner

 

DNRS Interactive DVD Series & Seminars

Postinfectious irritable bowel syndrome

 

 

 

 

J Pediatr Gastroenterol Nutr. 2009 Apr;48 Suppl 2:S95-7.

 

Postinfectious irritable bowel syndrome.

 

Barbara G, Cremon C, Pallotti F, De Giorgio R, Stanghellini V, Corinaldesi R.Department of Internal Medicine and Gastroenterology and CRBA, University of Bologna, Bologna, Italy. This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by abdominal pain and changes in bowel habits, not sustained by structural changes. There is now consistent evidence indicating that IBS may be the adverse outcome of an acute episode of infectious gastroenteritis, the so-called postinfectious (PI) IBS. The infectious agents involved in the development of PI-IBS include pathogenic bacteria, parasites, and viruses. Abdominal pain and diarrhea are the most common symptoms of PI-IBS. Several studies identified a number of risk factors increasing the susceptibility for PI-IBS development. These include the virulence of the pathogen, the severity, and duration of the acute enteritis, younger age, female sex, and psychological disturbances. Several mucosal abnormalities in the colon or ileum of patients who develop PI-IBS have been described. These changes include increased mucosal permeability, an increased amount of intraepithelial lymphocytes, lamina propria T cells, and mast cells, as well as serotonin-containing enteroendocrine cells. The mediators released by these activated cells may evoke enteric nervous system responses, excite sensory afferent pathways, and induce visceral hyperalgesia. Little is known about the prognosis of PI-IBS, although it is likely better than that of nonspecific IBS. There is little evidence about a specific treatment for PI-IBS. Although probiotics and antibiotics may be promising in the prevention of PI-IBS, the efficacy of these treatments should be assessed in an ad hoc designed study.

 

PMID: 19300138 [PubMed - indexed for MEDLINE]

 

 

 

{mosgoogle}

 

{mos_sb_discuss:11}

 


 

 

Related Articles:

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner